-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
2021 Nian 8 Yue 7 days, marked a new Limited ( BioShin Limited's ) officially announced a new type of glutamate modulators Troriluzole ( BHV4157 ) has recently won the State Drug Administration Drug Approval Center approval to carry out related obsessive-compulsive disorder Clinical trials include a phase III international multi-center trial for obsessive-compulsive disorder in China (study number: BHV4157-303 ) and a pharmacokinetic trial of healthy subjects in China (study number: BHV4157-110 )
.
,2021 Nian 8 Yue 7 days, marked a new Limited ( BioShin Limited's ) officially announced a new type of glutamate modulators Troriluzole ( BHV4157 ) has recently won the State Drug Administration Drug Approval Center approval to carry out related obsessive-compulsive disorder Clinical trials include a phase III international multi-center trial for obsessive-compulsive disorder in China (study number: BHV4157-303 ) and a pharmacokinetic trial of healthy subjects in China (study number: BHV4157-110 )
Obsessive-compulsive disorder is a type of anxiety disorder.
Troriluzole is a new type of glutamate regulator, and glutamate is the most abundant excitatory neurotransmitter in the human body
"At present, drugs are still the main means of treating obsessive-compulsive disorder.
However, the effective rate of drugs and behavioral treatments for obsessive-compulsive disorder is only between 40-50% .
Patients have to bear a great mental burden every day, and their lives are severely affected.
How to solve the patients’ unmet need for treatment is
extremely urgent .
" Biaoxin CEO Karl Lintel said: “ As a leading biopharmaceutical company in the industry, Biaoxin is committed to discovering, developing and commercializing new treatment methods to help China and The quality of life of patients with neurological diseases in the Asia-Pacific region has improved.
The rapid approval of the clinical trial application of Troriluzole in China is an exciting start, marking that Troriluzole 's research and development in China has entered a critical stage.
I believe that in the near future, we It can find safer and more effective treatments for Chinese patients with obsessive-compulsive disorder, and bring them new treatment options
.
" Leave a message here
